Phenylalanine hydroxylase misfolding and pharmacological chaperones

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2534-2545

  Underhaug, Jarl ^a   Aubi, Oscar ^a   Martinez, Aurora ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Folding aids; High throughput screening; Pharmachaperones; Pharmacophore modeling; Phenylalanine hydroxylase

Indexed keywords

CHAPERONE; PHENYLALANINE 4 MONOOXYGENASE; TETRAHYDROBIOPTERIN; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ARTICLE; BREATH ANALYSIS; CATABOLISM; DERIVATIZATION; ENZYME ACTIVITY; FLUOROMETRY; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; INBORN ERROR OF METABOLISM; LOSS OF FUNCTION MUTATION; MOLECULAR DOCKING; PERSONALIZED MEDICINE; PHARMACOPHORE; PHENYLKETONURIA; PROTEIN FOLDING; RENATURATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BIOPTERIN; DISEASE MODELS, ANIMAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDIVIDUALIZED MEDICINE; MICE; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; PROTEIN FOLDING; TYROSINE 3-MONOOXYGENASE;

EID: 84874929066     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220008     Document Type: Article

References (108)

1. Fölling, A., Über ausscheidung von phenylbrenztraubensäure in den harn als stoffwechselanomalie in verbindung mit imbezillitat Hoppe-Seyl. Z., 1934, 227, 169-176.
2. Blau, N.; van Spronsen, F. J.; Levy, H. L., Phenylketonuria. Lancet, 2010, 376, 1417-1427.
3. van Spronsen, F. J., Phenylketonuria: a 21st century perspective. Nat. Rev. Endocrinol., 2010, 6, 509-514.
4. de Groot, M. J.; Hoeksma, M.; Blau, N.; Reijngoud, D. J.; van Spronsen, F. J., Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol. Genet. Metab., 2010, 99 Suppl 1, S86-S89.
5. Scriver, C. R., The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat., 2007, 28, 831-845.
6. Mitchell, J. J.; Trakadis, Y. J.; Scriver, C. R., Phenylalanine hydroxylase deficiency. Genet. Med., 2011, 13, 697-707.
7. Guthrie, R.; Susi, A., A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants. Pediatrics, 1963, 32, 338-343.
8. Scriver, C. R.; Hurtubise, M.; Konecki, D.; Phommarinh, M.; Prevost, L.; Erlandsen, H.; Stevens, R.; Waters, P. J.; Ryan, S.; McDonald, D.; Sarkissian, C., PAHdb 2003: what a locus-specific knowledgebase can do. Hum. Mutat., 2003, 21, 333-344.
9. Enns, G. M.; Koch, R.; Brumm, V.; Blakely, E.; Suter, R.; Jurecki, E., Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol. Genet. Metab., 2010, 101, 99-109.
10. Scriver, C. R.; Kaufman, S., Hyperphenylalaninemia:phenylalanine hydroxylase defciency. In: The Metabolic and Molecular bases of Inherited Disease, 8th ed.; Scriver, C. R.; Beaudet, A. L.; Valle, D.; Sly, W. S., Eds. McGraw-Hill: New York, 2001; pp 1667-1724.
11. Werner, E. R.; Blau, N.; Thony, B., Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem. J., 2011, 438, 397-414.
12. Fitzpatrick, P. F., The aromatic amino acid hydroxylases. Adv. Enzymol. Relat. Areas Mol. Biol., 2000, 74, 235-294.
13. Fitzpatrick, P. F., Mechanism of aromatic amino acid hydroxylation. Biochemistry, 2003, 42, 14083-14091.
14. Flatmark, T.; Stevens, R. C., Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem. Rev., 1999, 99, 2137-2160.
15. Teigen, K.; McKinney, J. A.; Haavik, J.; Martinez, A., Selectivity and affinity determinants for ligand binding to the aromatic amino Acid hydroxylases. Curr. Med. Chem., 2007, 14, 455-467.
16. Matthes, S.; Mosienko, V.; Bashammakh, S.; Alenina, N.; Bader, M., Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology, 2010, 85, 95-109.
17. Walther, D. J.; Peter, J. U.; Bashammakh, S.; Hortnagl, H.; Voits, M.; Fink, H.; Bader, M., Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 2003, 299, 76.
18. Koehntop, K. D.; Emerson, J. P.; Que, L., Jr., The 2-His-1-carboxylate facial triad: a versatile platform for dioxygen activation by mononuclear non-heme iron(II) enzymes. J.Biol. Inorg. Chem., 2005, 10, 87-93.
19. Fusetti, F.; Erlandsen, H.; Flatmark, T.; Stevens, R. C., Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J. Biol. Chem., 1998, 273, 16962-16967.
20. Goodwill, K. E.; Sabatier, C.; Marks, C.; Raag, R.; Fitzpatrick, P. F.; Stevens, R. C., Crystal structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative diseases. Nat. Struct. Biol., 1997, 4, 578-585.
21. Erlandsen, H.; Fusetti, F.; Martínez, A.; Hough, E.; Flatmark, T.; Stevens, R. C., Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria. Nat. Struct. Biol., 1997, 4, 995-1000.
22. Kobe, B.; Jennings, I. G.; House, C. M.; Michell, B. J.; Goodwill, K. E.; Santarsiero, B. D.; Stevens, R. C.; Cotton, R. G.; Kemp, B. E., Structural basis of autoregulation of phenylalanine hydroxylase. Nat. Struct. Biol., 1999, 6, 442-448.
23. Teigen, K.; Frøystein, N. Å.; Martínez, A., The structural basis of the recognition of phenylalanine and pterin cofactors by phenylalanine hydroxylase: implications for the catalytic mechanism. J. Mol. Biol., 1999, 294, 807-823.
24. Teigen, K.; Dao, K. K.; McKinney, J. A.; Gorren, A. C.; Mayer, B.; Froystein, N. A.; Haavik, J.; Martinez, A., Tetrahydrobiopterin binding to aromatic amino acid hydroxylases. Ligand recognition and specificity. J. Med. Chem., 2004, 47, 5962-5971.
25. Erlandsen, H.; Bjørgo, E.; Flatmark, T.; Stevens, R. C., Crystal Structure and Site-Specific Mutagenesis of Pterin-Bound Human Phenylalanine Hydroxylase. Biochemistry, 2000, 39, 2208-2217.
26. Andersen, O. A.; Stokka, A. J.; Flatmark, T.; Hough, E., 2.0A resolution crystal structures of the ternary complexes of human phenylalanine hydroxylase catalytic domain with tetrahydrobiopterin and 3-(2-thienyl)-L-alanine or L-norleucine: substrate specificity and molecular motions related to substrate binding. J. Mol. Biol., 2003, 333, 747-757.
27. Erlandsen, H.; Stevens, R. C., The structural basis of phenylketonuria. Mol. Genet. Metab., 1999, 68, 103-125.
28. Pey, A. L.; Stricher, F.; Serrano, L.; Martinez, A., Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet., 2007, 81, 1006-1024.
29. Olsson, E.; Teigen, K.; Martinez, A.; Jensen, V. R., The Aromatic Amino Acid Hydroxylase Mechanism: A Perspective from Computational Chemistry. Adv. Inorg. Chem., 2010, 62, 437-500.
30. Eser, B. E.; Barr, E. W.; Frantom, P. A.; Saleh, L.; Bollinger, J. M., Jr.; Krebs, C.; Fitzpatrick, P. F., Direct spectroscopic evidence for a high-spin Fe(IV) intermediate in tyrosine hydroxylase. J. Am. Chem. Soc., 2007, 129, 11334-11335.
31. Kaufman, S., The phenylalanine hydroxylating system. Adv. Enzymol. Relat. Areas Mol. Biol., 1993, 67, 77-264.
32. Fitzpatrick, P. F., Allosteric regulation of phenylalanine hydroxylase. Arch. Biochem. Biophys., 2012, 519, 194-201.
33. Mitnaul, L. J.; Shiman, R., Coordinate regulation of tetrahydrobiopterin turnover and phenylalanine hydroxylase activity in rat liver cells. Proc. Natl. Acad. Sci. U S A, 1995, 92, 885-889.
34. Pey, A. L.; Thórólfsson, M.; Teigen, K.; Ugarte, M.; Martínez, A., Thermodynamic characterization of the binding of tetrahydropterins to phenylalanine hydroxylase. J. Am. Chem. Soc., 2004, 126, 13670-13678.
35. Gregersen, N.; Bross, P.; Vang, S.; Christensen, J. H., Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet., 2006, 7, 103-124.
36. Gersting, S. W.; Kemter, K. F.; Staudigl, M.; Messing, D. D.; Danecka, M. K.; Lagler, F. B.; Sommerhoff, C. P.; Roscher, A. A.; Muntau, A. C., Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet., 2008, 83, 5-17.
37. Waters, P. J., How PAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: insights from in vitro expression. Hum. Mutat., 2003, 21, 357-369.
38. Leandro, J.; Simonsen, N.; Saraste, J.; Leandro, P.; Flatmark, T., Phenylketonuria as a protein misfolding disease: The mutation pG46S in phenylalanine hydroxylase promotes self-association and fibril formation. Biochim. Biophys. Acta, 2011, 1812, 106-120.
39. Sarkissian, C. N.; Ying, M.; Scherer, T.; Thony, B.; Martinez, A., The mechanism of BH(4) -responsive hyperphenylalaninemia - as it occurs in the ENU1/2 genetic mouse model. Hum. Mutat., 2012, 33(10): 1464-1473.
40. Kraft, C.; Peter, M.; Hofmann, K., Selective autophagy: ubiquitin-mediated recognition and beyond. Nat. Cell. Biol., 2010, 12, 836-841.
41. Ding, Z.; Georgiev, P.; Thony, B., Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther., 2006, 13, 587-593.
42. Ding, Z.; Harding, C. O.; Rebuffat, A.; Elzaouk, L.; Wolff, J. A.; Thony, B., Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Therapy, 2008, 16, 673-681.
43. Matalon, R.; Michals-Matalon, K.; Bhatia, G.; Burlina, A. B.; Burlina, A. P.; Braga, C.; Fiori, L.; Giovannini, M.; Grechanina, E.; Novikov, P.; Grady, J.; Tyring, S. K.; Guttler, F., Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis., 2007, 30, 153-158.
44. Sarkissian, C. N.; Gamez, A.; Wang, L.; Charbonneau, M.; Fitzpatrick, P.; Lemontt, J. F.; Zhao, B.; Vellard, M.; Bell, S. M.; Henschell, C.; Lambert, A.; Tsuruda, L.; Stevens, R. C.; Scriver, C. R., Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. U S A, 2008, 105, 20894-20899.
45. Sarkissian, C. N.; Kang, T. S.; Gamez, A.; Scriver, C. R.; Stevens, R. C., Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria. Mol. Genet. Metab., 2011, 104, 249-254.
46. Erlandsen, H.; Pey, A. L.; Gamez, A.; Perez, B.; Desviat, L. R.; Aguado, C.; Koch, R.; Surendran, S.; Tyring, S.; Matalon, R.; Scriver, C. R.; Ugarte, M.; Martinez, A.; Stevens, R. C., Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. U S A, 2004, 101, 16903-16908.
47. van Spronsen, F. J.; Enns, G. M., Future treatment strategies in phenylketonuria. Mol. Genet. Metab., 2010, 99 Suppl 1, S90-S95.
48. Perez, B.; Rodriguez-Pascau, L.; Vilageliu, L.; Grinberg, D.; Ugarte, M.; Desviat, L. R., Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J. Inherit. Metab. Dis., 2010, 33, 397-403.
49. Brasil, S.; Viecelli, H. M.; Meili, D.; Rassi, A.; Desviat, L. R.; Perez, B.; Ugarte, M.; Thony, B., Pseudoexon exclusion by antisense therapy in 6-pyruvoyl-tetrahydropterin synthase deficiency. Hum. Mutat., 2011, [Epub a head of print].
50. Pey, A. L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A., Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest., 2008, 118, 2858-2867.
51. Santos-Sierra, S.; Kirchmair, J.; Perna, A. M.; Reiss, D.; Kemter, K.; Roschinger, W.; Glossmann, H.; Gersting, S. W.; Muntau, A. C.; Wolber, G.; Lagler, F. B., Novel pharmacological chaperones that correct phenylketonuria in mice. Hum. Mol. Genet., 2012, 21, 1877-1887.
52. Bukau, B.; Weissman, J.; Horwich, A., Molecular chaperones and protein quality control. Cell, 2006, 125, 443-451.
53. Kriegenburg, F.; Ellgaard, L.; Hartmann-Petersen, R., Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation. The FEBS journal, 2012, 279, 532-542.
54. Cattaneo, M.; Dominici, R.; Cardano, M.; Diaferia, G.; Rovida, E.; Biunno, I., Molecular chaperones as therapeutic targets to counteract proteostasis defects. J. Cell. Physiol., 2012, 227, 1226-1234.
55. Brandt, G. E.; Blagg, B. S., Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr. Top. Med. Chem., 2009, 9, 1447-1461.
56. Cohen, F. E.; Kelly, J. W., Therapeutic approaches to protein-misfolding diseases. Nature, 2003, 426, 905-909.
57. Ozcan, U.; Yilmaz, E.; Ozcan, L.; Furuhashi, M.; Vaillancourt, E.; Smith, R. O.; Gorgun, C. Z.; Hotamisligil, G. S., Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 2006, 313, 1137-1140.
58. Leandro, P.; Lechner, M. C.; Tavares de Almeida, I.; Konecki, D., Glycerol increases the yield and activity of human phenylalanine hydroxylase mutant enzymes produced in a prokaryotic expression system. Mol. Genet. Metab., 2001, 73, 173-178.
59. Nascimento, C.; Leandro, J.; Tavares de Almeida, I.; Leandro, P., Modulation of the activity of newly synthesized human phenylalanine hydroxylase mutant proteins by low-molecular-weight compounds. Protein J., 2008, 27, 392-400.
60. Perlmutter, D. H., Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res., 2002, 52, 832-836.
61. Bernier, V.; Lagace, M.; Bichet, D. G.; Bouvier, M., Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab., 2004, 15, 222-228.
62. Loo, T. W.; Clarke, D. M., Chemical and pharmacological chaperones as new therapeutic agents. Expert Rev. Mol. Med., 2007, 9, 1-18.
63. Morello, J. P.; Petaja-Repo, U. E.; Bichet, D. G.; Bouvier, M., Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci., 2000, 21, 466-469.
64. Fan, J. Q., A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol. Chem., 2008, 389, 1-11.
65. Kure, S.; Hou, D. C.; Ohura, T.; Iwamoto, H.; Suzuki, S.; Sugiyama, N.; Sakamoto, O.; Fujii, K.; Matsubara, Y.; Narisawa, K., Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr., 1999, 135, 375-378.
66. Muntau, A. C.; Roschinger, W.; Habich, M.; Demmelmair, H.; Hoffmann, B.; Sommerhoff, C. P.; Roscher, A. A., Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med., 2002, 347, 2122-2132.
67. Blau, N.; Hennermann, J. B.; Langenbeck, U.; Lichter-Konecki, U., Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol. Genet. Metab., 2011, 104 Suppl: S2-S9.
68. Levy, H. L.; Milanowski, A.; Chakrapani, A.; Cleary, M.; Lee, P.; Trefz, F. K.; Whitley, C. B.; Feillet, F.; Feigenbaum, A. S.; Bebchuk, J. D.; Christ-Schmidt, H.; Dorenbaum, A., Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet, 2007, 370, 504-510.
69. Pey, A. L.; Perez, B.; Desviat, L. R.; Martinez, M. A.; Aguado, C.; Erlandsen, H.; Gamez, A.; Stevens, R. C.; Thorolfsson, M.; Ugarte, M.; Martínez, A., Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat., 2004, 24, 388-399.
70. Kure, S.; Sato, K.; Fujii, K.; Aoki, Y.; Suzuki, Y.; Kato, S.; Matsubara, Y., Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab.urano, 2004, 83, 150-156.
71. Rost, B.; Sander, C.; Schneider, R., PHD, an automatic mail server for protein structure prediction. Comput. Appl. Biosci., 1994, 10, 53-60.
72. Urano, F.; Hayashi, N.; Arisaka, F.; Kurita, H.; Murata, S.; Ichinose, H., Molecular mechanism for pterin-mediated inactivation of tyrosine hydroxylase: formation of insoluble aggregates of tyrosine hydroxylase. J. Biochem. (Tokyo), 2006, 139, 625-635.
73. Thöny, B.; Calvo, A. C.; Scherer, T.; Svebak, R. M.; Haavik, J.; Blau, N.; Martinez, A., Tetrahydrobiopterin shows chaperone activity for tyrosine hydroxylase. J. Neurochem., 2008, 106, 672-681.
74. Sanchez-Ruiz, J. M., Ligand effects on protein thermodynamic stability. Biophys. Chem., 2007, 126, 43-49.
75. Tropak, M. B.; Blanchard, J. E.; Withers, S. G.; Brown, E. D.; Mahuran, D., High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol., 2007, 14, 153-164.
76. Ringe, D.; Petsko, G. A., What are pharmacological chaperones and why are they interesting? J. Biol., 2009, 8, 80.
77. Parenti, G., Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med., 2009, 1, 268-279.
78. Valenzano, K. J.; Khanna, R.; Powe, A. C.; Boyd, R.; Lee, G.; Flanagan, J. J.; Benjamin, E. R., Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug. Dev. Technol., 2011, 9, 213-235.
79. Sampson, H. M.; Robert, R.; Liao, J.; Matthes, E.; Carlile, G. W.; Hanrahan, J. W.; Thomas, D. Y., Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem. Biol., 2011, 18, 231-242.
80. Gautherot, J.; Durand-Schneider, A. M.; Delautier, D.; Delaunay, J. L.; Rada, A.; Gabillet, J.; Housset, C.; Maurice, M.; Ait-Slimane, T., Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4. J. Biol. Chem., 2012, 287, 5070-5078.
81. Misawa, T.; Hayashi, H.; Sugiyama, Y.; Hashimoto, Y., Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2. Bioorg. Med. Chem., 2012, 20(9): 2940-2949.
82. Skjevik, A. A.; Teigen, K.; Martinez, A., Overview of computational methods employed in early-stage drug discovery. Fut. Med. Chem., 2009, 1, 49-63.
83. Kubinyi, H., Success stories of computer-aided design. In: Computer Applications in Pharmaceutical Research and Development Ekins, S ed.; Wiley-Interscience: 2006; pp 377-424.
84. Yang, S. Y., Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today, 2010, 15, 444-450.
85. Noorwez, S. M.; Ostrov, D. A.; McDowell, J. H.; Krebs, M. P.; Kaushal, S., A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest. Ophthalmol. Vis. Sci., 2008, 49, 3224-3230.
86. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-1749.
87. Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I., Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug. Discov., 2003, 2, 369-378.
88. Wermuth, C.-G.; Ganellin, C. R.; Lindberg, P.; Mitscher, L. A., Glossary of Terms Used in Medicinal Chemistry (IUPAC Recommendations 1997). Annu. Rep. Med. Chem., 1998, 33, 385-395.
89. Sun, H., Pharmacophore-based virtual screening. Curr. Med. Chem., 2008, 15, 1018-1024.
90. Mayr, L. M.; Bojanic, D., Novel trends in high-throughput screening. Curr Opin Pharmacol, 2009, 9, 580-588.
91. Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V. S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S., Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov., 2011, 10, 188-195.
92. Keseru, G. M.; Makara, G. M., Hit discovery and hit-to-lead approaches. Drug Discov. Today, 2006, 11, 741-748.
93. Zheng, W.; Padia, J.; Urban, D. J.; Jadhav, A.; Goker-Alpan, O.; Simeonov, A.; Goldin, E.; Auld, D.; LaMarca, M. E.; Inglese, J.; Austin, C. P.; Sidransky, E., Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. U S A, 2007, 104, 13192-13197.
94. Goldin, E.; Zheng, W.; Motabar, O.; Southall, N.; Choi, J. H.; Marugan, J.; Austin, C. P.; Sidransky, E., High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS ONE, 2012, 7, e29861.
95. Shanmuganathan, M.; Britz-McKibbin, P., Inhibitor screening of pharmacological chaperones for lysosomal b-glucocerebrosidase by capillary electrophoresis. Anal. Bioanal. Chem., 2011, 399, 2843-2853.
96. Pantoliano, M. W.; Petrella, E. C.; Kwasnoski, J. D.; Lobanov, V. S.; Myslik, J.; Graf, E.; Carver, T.; Asel, E.; Springer, B. A.; Lane, P.; Salemme, F. R., High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen., 2001, 6, 429-440.
97. Niesen, F. H.; Berglund, H.; Vedadi, M., The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc., 2007, 2, 2212-2221.
98. Lo, M.-C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G., Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem., 2004, 332, 153-159.
99. Stevens, R. C.; Sancho, J.; Martinez, A., Rescue of misfolded proteins and stabilization by small molecules. Methods Mol. Biol., 2010, 648, 313-324.
100. Maynard, J. A.; Lindquist, N. C.; Sutherland, J. N.; Lesuffleur, A.; Warrington, A. E.; Rodriguez, M.; Oh, S.-H., Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol. J., 2009, 4, 1542-1558.
101. Flatmark, T.; Stokka, A. J.; Berge, S. V., Use of surface plasmon resonance for real-time measurements of the global conformational transition in human phenylalanine hydroxylase in response to substrate binding and catalytic activation. Anal. Biochem., 2001, 294, 95-101.
102. Stokka, A. J.; Flatmark, T., Substrate-induced conformational transition in human phenylalanine hydroxylase as studied by surface plasmon resonance analyses: the effect of terminal deletions, substrate analogues and phosphorylation. Biochem. J., 2003, 369, 509-518.
103. Flatmark, T.; Almås, B.; Knappskog, P. M.; Berge, S. V.; Svebak, R. M.; Chehin, R.; Muga, A.; Martínez, A., Tyrosine hydroxylase binds tetrahydrobiopterin cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection. Eur. J. Biochem., 1999, 262, 840-849.
104. Torreblanca, R.; Lira-Navarrete, E.; Sancho, J.; Hurtado-Guerrero, R., Structural and Mechanistic Basis of the Interaction between a Pharmacological Chaperone and Human Phenylalanine Hydroxylase. Chembiochem., 2012, 13 1266-1269.
105. Treacy, E. P.; Delente, J. J.; Elkas, G.; Carter, K.; Lambert, M.; Waters, P. J.; Scriver, C. R., Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study. Pediatr. Res., 1997, 42, 430-435.
106. Calvo, A. C.; Scherer, T.; Pey, A. L.; Ying, M.; Winge, I.; McKinney, J.; Haavik, J.; Thony, B.; Martinez, A., Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2. J. Neurochem., 2010, 114, 853-863.
107. Daubner, S. C.; Le, T.; Wang, S., Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508, 1-12.
108. Demirkol, M.; Gizewska, M.; Giovannini, M.; Walter, J., Follow up of phenylketonuria patients. Mol. Genet. Metab., 2011, 104 Suppl, S31-S39.